Kariminejad Neurodevelopmental Syndrome (KAREVS) — Comprehensive Disease Characterization

Disease: Kariminejad Neurodevelopmental Syndrome (KAREVS) MONDO: MONDO:0975795 · OMIM: #620937 · Gene: RBSN (rabenosyn-5 / ZFYVE20; OMIM *609511; HGNC:20759) Category: Mendelian, autosomal recessive Evidence base: Predominantly human clinical (2 families, 6 individuals) plus in-vitro/cell-biology and model-organism data on RBSN/rabenosyn-5 function.

Note on evidence strength. KAREVS is an ultra-rare, recently delineated Mendelian disorder described in only two families. Consequently, most clinical statements derive from small aggregated case-level reports (OMIM/primary papers), and many template fields (formal prevalence, survival statistics, QoL instruments, trials) have no published data; these are marked Not available. Mechanistic claims are supported by direct functional studies of RBSN in patient cells and model organisms.

Summary (Answer to the Research Question)

Kariminejad Neurodevelopmental Syndrome (KAREVS) is an autosomal recessive neurodevelopmental/neuromuscular disorder caused by biallelic missense variants in the FYVE domain of RBSN (rabenosyn-5), an endosomal Rab4/Rab5 effector. It is characterized by global developmental delay/mild-to-moderate intellectual disability, progressive muscle weakness (myopathy, sometimes with sensorimotor neuropathy or spastic paraplegia), distinctive facial dysmorphism, ophthalmoplegia/ocular anomalies, and variable, nonspecific brain-imaging abnormalities (leukoencephalopathy/delayed myelination). Mechanistically, the FYVE variants abolish binding to phosphatidylinositol-3-phosphate (PI3P), preventing rabenosyn-5 recruitment to early endosomes and thereby delaying endosomal maturation and impairing endolysosomal degradation while sparing endosomal recycling — a "separation-of-function" defect. Management is entirely supportive; recurrence risk is 25% and consanguinity is the principal risk factor.

1. Disease Information

Overview. KAREVS (OMIM #620937) is a rare autosomal recessive developmental disorder featuring global developmental delay (delayed walking by a few years, speech delay), impaired intellectual development, hypotonia and progressive muscle weakness, dysmorphic facial features, and variable nonspecific brain-imaging abnormalities. It was first delineated clinically by Kariminejad et al. (2015) in three Iranian siblings and molecularly resolved (gene = RBSN) by Paul et al. (2022) [PMID 26192890; 35652444].

"two distinct RBSN missense variants are responsible for a novel Mendelian disorder consisting of progressive muscle weakness, facial dysmorphisms, ophthalmoplegia and intellectual disability." — Paul et al., 2022 (35652444)

Key identifiers. - OMIM: #620937 (phenotype); *609511 (RBSN gene) - MONDO: MONDO:0975795 - MedGen: C5975371 - Orphanet: No dedicated ORPHAcode identified as of report date (Not available) - ICD-10: No specific code; maps to Q87.8 / F79 (general dysmorphic/ID categories) (no dedicated code) - ICD-11: No specific code; would fall under LD2F.1Y / 6A00 classes (no dedicated code) - MeSH: No dedicated MeSH heading (Not available)

Synonyms / alternative names. Kariminejad neurodevelopmental syndrome; KAREVS; "Intellectual disability, muscle weakness and characteristic face" (original descriptive title, 3p24.3–p25.3-linked recessive syndrome). Not to be confused with Kariminejad-Nafissi syndrome (a distinct skeletal dysplasia).

Data provenance. Disease-level aggregated resources (OMIM, MONDO, MedGen) built from individual patient case reports (2 families, n=6). No EHR/registry-scale data exist.

2. Etiology

Causal factor — genetic (Mendelian, monogenic). KAREVS is caused by homozygous missense variants in RBSN. No environmental, infectious, or multifactorial etiology is involved.

Genetic risk factors. - Causal variants: c.547G>A (p.Gly183Arg) — Iranian family; c.538C>G (p.Arg180Gly) — Canadian Cree family (both NM_022340.3, FYVE domain) [PMID 35652444]. - Consanguinity is the dominant risk factor: both families are consanguineous and homozygous by descent. - Being a heterozygous carrier of a pathogenic RBSN allele confers risk of affected offspring only when both parents carry it (AR). - Modifier genes: none identified; phenotypic variability (below) is currently unexplained (candidate modifiers not studied).

Environmental / lifestyle / occupational risk factors. Not applicable — no non-genetic contributors are known or expected for a monogenic recessive disorder.

Protective factors. None described. In principle, absence of a second pathogenic allele (heterozygosity) is fully protective (carriers are unaffected) [PMID 26192890].

Gene–environment interactions. None described.

3. Phenotypes

All phenotypes derive from n=6 patients; "frequencies" are qualitative/small-count estimates from Kariminejad 2015 (Iranian family, F1) and Paul 2022 / OMIM clinical synopsis (Cree family, F2).

"...mild intellectual disability, progressive muscle weakness, and characteristic facies... highly arched eyebrows, down-slanting palpebral fissures, prominent nasal bridge, prominent nose, columella extending below alae nasi, narrow mouth, narrow palate, and dental caries, and in one of them an inability to abduct the left eye." — Kariminejad et al., 2015 (26192890)

Quality-of-life impact. No formal QoL instruments (EQ-5D/SF-36/PROMIS) have been applied (Not available). Expected functional impact: lifelong intellectual disability limiting independent living, plus progressive weakness/spasticity affecting mobility and self-care.

4. Genetic / Molecular Information

• Causal gene: RBSN (Rabenosyn, RAB effector; aliases ZFYVE20, RBSN5). HGNC:20759; NCBI Gene 64145; Ensembl ENSG00000131381; UniProt Q9H1K0; OMIM *609511; cytoband 3p25.3.
• Pathogenic variants (KAREVS):
• c.547G>A, p.Gly183Arg (homozygous; Iranian F1)
• c.538C>G, p.Arg180Gly (homozygous; Cree F2)
• Both are missense, in the FYVE domain, germline, homozygous; classified pathogenic/likely pathogenic (ACMG: segregation, functional evidence, extreme rarity). p.Arg180Gly is present only once in gnomAD (allele frequency <1×10⁻⁵); p.Gly183Arg is absent/ultra-rare [PMID 35652444].
• Functional consequence: selective (separation-of-function) loss of function — loss of PI3P binding → failure of early-endosome localization → impaired endosomal maturation/lysosomal degradation with preserved recycling [PMID 35652444].
• Allelic series (distinct RBSN disorders):
• p.Gly425Arg (ZFYVE20 c.1273G>A): severe multi-organ disorder — intractable seizures, developmental delay, microcephaly, dysostosis, osteopenia, dysmorphism, macrocytosis/megaloblastoid erythropoiesis, transient cobalamin deficiency, hypertriglyceridemia, partial cathepsin D deficiency, 50% reduced transferrin uptake (recycling defect) [PMID 25233840].
• Biallelic loss-of-function: MFANDO — Myelofibrosis, Congenital, with Anemia, Neutropenia, Developmental delay, and Ocular abnormalities (OMIM #620939). Caused by homozygous c.289G>C, p.(Gly97Arg) (NM_022340.3), which actually disrupts splicing of exon 5 → absence of intact RBSN (true loss of function) with larger, clustered EEA1-positive endosomes in patient fibroblasts. Three consanguineous sibs: congenital progressive myelofibrosis (reticulin fibrosis by 4 weeks), anemia, severe congenital neutropenia (filgrastim-refractory), thrombocytopenia, developmental delay, ocular anomalies, dysmorphism; proband died at 20 months with 46,XY complete sex reversal and sensorineural hearing loss; hematopoietic stem-cell/bone-marrow transplant restored blood counts in surviving sibs (Magoulas et al., 2018, 29784638). This is the key allelic contrast: KAREVS lacks hematologic disease and is caused by hypomorphic FYVE missense alleles, whereas MFANDO is a true-LoF, hematologic/multisystem disorder.

"distinct germline mutations in RBSN cause non-overlapping phenotypes with specific and discrete endolysosomal cellular defects." — Paul et al., 2022 (35652444)

• Somatic vs germline: germline only; no somatic/cancer association in patients (though complete loss is a tumor-suppressor phenotype in Drosophila).
• Modifier genes / epigenetics: none identified (Not available).
• Chromosomal abnormalities: none — disease is a point-mutation (missense) disorder; CMA/karyotype normal.

Ontology. Gene product: FYVE-domain Rab effector. GO-MF: phosphatidylinositol-3-phosphate binding GO:0032266; Rab GTPase binding GO:0017137. CHEBI: phosphatidylinositol 3-phosphate CHEBI:26034.

5. Environmental Information

Not applicable. KAREVS is a monogenic recessive disorder with no established environmental factors, lifestyle contributors, or infectious agents. No toxin/radiation/occupational exposures are implicated (searches of CTD/PubMed yield no environmental modifiers).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Homozygous FYVE-domain missense variant (p.Gly183Arg or p.Arg180Gly) in RBSN results in an amino-acid substitution at a conserved residue of the phosphoinositide-binding FYVE finger. (Demonstrated — genetics/segregation.)
2. The altered FYVE domain abolishes binding to phosphatidylinositol-3-phosphate (PI3P). (Demonstrated — biochemistry.)
3. Loss of PI3P binding prevents translocation/recruitment of rabenosyn-5 to early endosomal membranes (mutant protein fails to co-localize with EEA1). (Demonstrated — cell imaging in patient fibroblasts.)
4. Endosome-unassociated rabenosyn-5 cannot properly scaffold the Rab5–VPS45–SNARE fusion/maturation machinery, leading to delayed early-to-late endosome maturation and impaired delivery of cargo to lysosomes. (Demonstrated — cargo tagged for lysosomal degradation accumulates.)
5. Critically, the endosomal recycling arm is spared (separation-of-function) — the pathway branches here, distinguishing KAREVS from the G425R recycling-defect disorder. (Demonstrated.)
6. Impaired endolysosomal degradation results in accumulation of undegraded cargo and disturbed membrane/receptor homeostasis in post-mitotic, trafficking-dependent cells (neurons, myofibers). (Inferred from cellular data → tissue phenotype.)
7. This leads to neuronal/white-matter dysfunction (→ intellectual disability, leukoencephalopathy, delayed myelination) and myofiber dysfunction (→ progressive myopathy; ± neuropathy/spastic paraplegia), plus developmental effects on craniofacial patterning (→ dysmorphism). (Inferred.)

Detail by category

• Molecular pathways: Rab5/Rab4 GTPase signaling on early endosomes; PI3-kinase→PI3P phosphoinositide signaling; SNARE-mediated membrane fusion via VPS45 (Sec1/Munc18). Not a classic Wnt/MAPK/mTOR disorder, though endolysosomal trafficking intersects growth-factor-receptor signaling.
• Cellular processes: early endosome fusion/maturation; receptor-mediated endocytosis; endosome-to-lysosome (degradative) transport; endosomal recycling (spared). Rabenosyn-5 "is recruited in a phosphatidylinositol-3-kinase-dependent fashion to early endosomes... complexed to the Sec1-like protein hVPS45" [PMID 11062261].
• Protein dysfunction: selective/partial loss of function — the protein is expressed but mislocalized; a hypomorphic/separation-of-function mechanism (not aggregation or dominant-negative). Complete loss is embryonic-lethal, so disease requires residual function.
• Metabolic changes: secondary and variable — elevated lactate and CK in some patients (suggesting mitochondrial/muscle stress); hyperlipidemia in one; the allelic G425R disorder shows cobalamin deficiency/hypertriglyceridemia (trafficking of nutrient receptors).
• Immune involvement: none in KAREVS (no hematologic/immune phenotype; contrast RBSN congenital myelofibrosis).
• Tissue damage mechanisms: inferred chronic cellular trafficking stress in neurons and myofibers; no fibrosis/ischemia mechanism.
• Biochemical abnormalities: loss of PI3P–FYVE interaction; partial cathepsin D processing defect described for the allelic G425R variant.
• Epigenetic changes / omics profiling: Not available (no transcriptomic/proteomic/metabolomic/single-cell datasets published for KAREVS).

Cell types (CL): neuron CL:0000540; skeletal muscle fiber CL:0000188; fibroblast (model) CL:0000057; oligodendrocyte (myelination, inferred) CL:0000128. Biological process (GO): endosome to lysosome transport GO:0008333; early endosome to late endosome transport GO:0045022; endosomal transport GO:0016197; regulation of endosome size/maturation; vesicle fusion GO:0006906.

7. Anatomical Structures Affected

• Organ/system level (primary): central nervous system (brain — cerebral white matter, hippocampus, ventricles) and skeletal muscle (neuromuscular system). Secondary/associated: peripheral nerves (sensorimotor neuropathy), eye/extraocular muscles (ophthalmoplegia, ptosis, refractive error), craniofacial skeleton (dysmorphism, maxillary hypoplasia), skeletal growth (short stature).
• Body systems: nervous (central + peripheral), musculoskeletal, ophthalmologic. Not primarily cardiovascular, respiratory, renal, or hematologic (distinguishing from allelic RBSN disorders).
• Tissue/cell level: nervous tissue (neurons, myelinating glia), striated muscle tissue (myofibers). Ubiquitously expressed gene, but post-mitotic trafficking-dependent tissues are most vulnerable.
• Subcellular level: early endosome (primary site of RBSN action) — GO cellular component early endosome GO:0005769, early endosome membrane GO:0031901; downstream lysosome GO:0005764; cytoplasmic vesicle. UniProt localizes rabenosyn-5 to the cytoplasmic face of early endosomes.
• Localization / UBERON: brain UBERON:0000955; cerebral white matter UBERON:0002316; hippocampus UBERON:0002421; lateral ventricle UBERON:0002285; skeletal muscle UBERON:0001134; peripheral nerve UBERON:0001021; extraocular muscle UBERON:0002417.
• Lateralization: generally bilateral/symmetric (developmental/systemic); the original ocular finding (impaired abduction) was reported as unilateral (left eye) in one patient.

8. Temporal Development

• Onset: congenital / early-childhood, insidious. Motor and speech delay evident in infancy; independent walking delayed to 18–25 months [PMID 26192890].
• Progression: chronic and slowly progressive, principally the neuromuscular component ("progressive muscle weakness"); intellectual disability is relatively static. Spastic paraplegia (Cree family) is progressive.
• Disease course: progressive/stable hybrid — cognitive impairment stable, motor/neuromuscular features progressive. No episodic/relapsing pattern.
• Duration: lifelong. Survival into adulthood documented (Paul 2022 followed the original Iranian family long-term).
• Remission: none (no spontaneous or treatment-induced remission).
• Critical periods: early childhood (developmental/rehabilitation window); no proven pharmacologic intervention window.

9. Inheritance and Population

• Epidemiology: ultra-rare. Only 6 individuals from 2 families reported worldwide (3 Iranian sibs; 3 Canadian Cree across 2 generations). Formal prevalence/incidence not established (consistent with <1/1,000,000).
• Inheritance: autosomal recessive (homozygous RBSN variants; unaffected consanguineous carrier parents) [PMID 26192890; 35652444].
• Penetrance: appears complete in homozygotes (all reported homozygotes affected); carriers unaffected.
• Expressivity: variable — the Cree family expanded the phenotype (spastic paraplegia, neuropathy, ↑CK/↑lactate, microcephaly, hyperlipidemia, enlarged ventricles) beyond the Iranian family.
• Genetic anticipation: none (not a repeat-expansion disorder).
• Germline mosaicism: none reported.
• Founder effects: the two alleles are family-private (G183R Iranian; R180G Cree) — plausibly founder alleles within each consanguineous kindred rather than a broad population founder variant.
• Consanguinity: central — both families consanguineous; homozygosity mapping was the key discovery tool.
• Carrier frequency: not defined; RBSN pathogenic alleles are extremely rare in gnomAD (R180G seen once).
• Population demographics: reported in Iranian and Canadian Indigenous (Cree) populations. Sex ratio ~1:1 (both sexes affected). Age distribution: pediatric-through-adult.

10. Diagnostics

• Definitive test: molecular genetic testing. In consanguineous families, homozygosity mapping + whole-exome (WES) or whole-genome (WGS) sequencing identifies biallelic RBSN variants (confirmed by Sanger segregation) [PMID 26192890; 35652444]. Single-gene/RBSN-inclusive neurodevelopmental or myopathy gene panels are appropriate when the phenotype is recognized.

  "Using exome sequencing, we identified recessively acting germline alleles p.Arg180Gly and p.Gly183Arg." — Paul et al., 2022 (35652444)

• CMA / karyotype / FISH: expected normal (no CNV/structural/aneuploidy cause) — useful mainly to exclude mimics.
• Mitochondrial DNA / repeat-expansion testing: not indicated for causation, but mtDNA studies may be considered to exclude mitochondrial disease given elevated lactate/CK in some patients.
• Supportive clinical tests:
• Electrophysiology (EMG/NCS): myopathic pattern; sensorimotor neuropathy in some [PMID 26192890].
• Muscle biopsy: nonspecific.
• Neuroimaging (MRI): leukoencephalopathy, delayed myelination, frontal/parietal white-matter hyperintensities, hippocampal atrophy, enlarged ventricles (variable).
• Labs: serum CK and lactate may be elevated in a subset; no specific biomarker.
• Omics-based diagnostics: none validated (Not available); functional PI3P-binding/endosomal-localization assays are research tools that can support variant interpretation.
• Clinical criteria: no formal consensus criteria; diagnosis = compatible phenotype + biallelic pathogenic RBSN variants.
• Differential diagnosis: other AR syndromic intellectual disability with myopathy and dysmorphism; congenital/metabolic myopathies; mitochondrial encephalomyopathies (↑lactate/CK); hereditary spastic paraplegias with cognitive involvement; and the distinct RBSN-opathies — the G425R seizure/microcephaly phenotype (25233840) and MFANDO congenital myelofibrosis with cytopenias (OMIM #620939, 29784638). Distinguishing feature of KAREVS: characteristic facies + progressive myopathy without hematologic abnormality, with FYVE-domain RBSN genotype.
• Screening: no newborn-screening assay. Carrier and cascade testing feasible once the family variant is known; prenatal / preimplantation genetic diagnosis feasible for at-risk pregnancies.

NCIT: Whole Exome Sequencing; Whole Genome Sequencing; Genetic Testing; Magnetic Resonance Imaging; Electromyography.

11. Outcome / Prognosis

• Survival / mortality: No disease-specific mortality data. Reported patients survived into adulthood; life-limiting complications not documented in the small cohort (formal survival statistics Not available).
• Morbidity / disability: Principal morbidity is lifelong intellectual disability plus a progressive neuromuscular disability (weakness ± spasticity/neuropathy) affecting mobility, and ocular/visual impairment. ICF-level functional limitations in mobility, communication, and self-care are expected.
• Quality-of-life measures: none applied (Not available).
• Complications: progressive weakness/contractures, spasticity, visual impairment; potential feeding/dental issues (narrow palate, caries). No organ failure described.
• Recovery potential: none (non-remitting); rehabilitation can improve function but not reverse the underlying deficit.
• Prognostic factors: genotype (allelic series predicts severity/organ involvement); presence of spastic paraplegia/neuropathy may portend greater motor disability. No validated prognostic biomarkers.

12. Treatment

No disease-modifying or curative therapy exists. Management is supportive, multidisciplinary, and symptom-directed (extrapolated from standard care for AR syndromic ID/myopathy; no KAREVS-specific trials).

• Pharmacotherapy: no targeted drug. Symptomatic agents as needed (e.g., antispasticity agents such as baclofen for spastic paraplegia; standard management of any seizures). Pharmacogenomics: none specific.
• Advanced therapeutics (gene/cell/RNA/targeted/immunotherapy): none available; entirely theoretical. Gene-replacement/editing is conceptually plausible (recessive LoF) but faces the barrier that complete loss is lethal and CNS delivery is unsolved — no programs exist (Not available).
• Surgical/interventional: as indicated for complications (e.g., strabismus/ptosis surgery, orthopedic management of contractures).
• Supportive & rehabilitative (mainstay): physical therapy (weakness, spasticity, contracture prevention), occupational therapy, speech-language therapy, special education/developmental support, ophthalmologic correction (refractive error, amblyopia, ptosis/strabismus), dental care, and nutritional support as needed.
• Experimental treatments / trials: none registered (Not available).
• Treatment outcomes / adverse events: no cohort data.
• Treatment strategy: individualized supportive care coordinated by clinical genetics, neurology, physiatry, ophthalmology, and rehabilitation services.

NCIT: Physical Therapy; Occupational Therapy; Speech Therapy; Supportive Care; Rehabilitation Therapy; Baclofen.

13. Prevention

• Primary prevention: genetic counseling for consanguineous couples and families with an affected child; carrier testing of at-risk relatives; preconception/prenatal counseling. Recurrence risk to siblings = 25%.
• Secondary prevention (early detection): cascade carrier screening in the extended family; prenatal diagnosis or preimplantation genetic testing (PGT-M) once the familial RBSN variant is known.
• Tertiary prevention: early developmental intervention, physiotherapy to prevent contractures, proactive ophthalmologic and dental care to limit complications.
• Immunization / public-health / environmental / behavioral / prophylaxis measures: Not applicable (no infectious/environmental component). Standard childhood immunizations as per general guidelines.
• Counseling: autosomal-recessive genetic counseling is the cornerstone of prevention (NSGC/ACMG frameworks).

NCIT: Genetic Counseling; Genetic Carrier Screening; Prenatal Diagnosis.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring KAREVS-equivalent disease is reported in any non-human species (OMIA: none). Human — Homo sapiens (NCBI:txid9606).
• Orthologous genes (NCBI Gene / model):
• Mouse Rbsn (MGI:1925537; UniProt Q80Y56)
• Drosophila Rbsn / CG8506
• C. elegans rabs-5
• S. cerevisiae functional homolog VAC1
• Natural disease in animals / veterinary relevance / breeds (VBO): none known (Not applicable).
• Comparative biology: the rabenosyn-5–VPS45–Rab5 endosomal-fusion module is deeply conserved from yeast to humans, so cellular disease mechanisms translate across species even though the human neurodevelopmental phenotype is not naturally observed elsewhere. "Rabenosyn-5 is a closer mammalian functional homologue of yeast Vac1p than EEA1." [PMID 11062261].
• Transmission / zoonotic potential: Not applicable (genetic, non-transmissible).

15. Model Organisms

• Cellular / in vitro (most relevant to KAREVS): patient-derived fibroblasts (p.Gly183Arg) demonstrate the disease mechanism — loss of punctate endosomal localization, failure to co-localize with EEA1, and accumulation of lysosome-targeted cargo [PMID 35652444]. iPSC-derived neurons/myotubes are logical (not yet published) models.
• Mouse (Rbsn, MGI:1925537): whole-body knockout is embryonic-lethal — recapitulates the essential trafficking role but not the viable human phenotype; a knock-in of the human missense (hypomorphic) allele or conditional/tissue-specific model would be required to model KAREVS. No published KAREVS mouse to date.
• Drosophila (Rbsn/CG8506): null mutants show defective early-endosome formation, loss of epithelial polarity, and neoplastic overgrowth (Rbsn as tumor suppressor), establishing the Rbsn–Vps45–Rab5–Avalanche fusion module in vivo [PMID 18685079].
• C. elegans (rabs-5 / vps-45): mutants show endocytic defects with accumulation of aberrantly small endosomes, confirming RABS-5/VPS-45 cooperation downstream of RAB-5 [PMID 17235359].
• Yeast (VAC1): the functional homolog coordinates Rab/PI3K signaling in VPS45-dependent endosomal docking/fusion [PMID 11062261].
• Phenotype recapitulation: model organisms faithfully reproduce the cellular/endosomal mechanism but not the specific human neurodevelopmental/neuromuscular disease, because null alleles are lethal and human disease arises from residual-function missense alleles. Model limitation: need for allele-specific (knock-in) and CNS/muscle-conditional models.
• Applications: these models illuminate endosomal fusion/maturation, PI3P–FYVE biology, and Rab5-effector function; allele-specific models would enable therapy testing.
• Resources: MGI (mouse), FlyBase (Drosophila), WormBase (C. elegans), SGD (yeast), IMPC/IMSR.

Supported vs. Refuted Hypotheses

Supported: - KAREVS is caused by biallelic FYVE-domain RBSN missense variants (AR) — strongly supported (segregation in 2 families + functional data) [PMID 26192890; 35652444]. - Mechanism is loss of PI3P binding → endosomal mislocalization → delayed endosomal maturation with spared recycling (separation-of-function) — supported (patient-cell biochemistry/imaging) [PMID 35652444]. - Distinct RBSN variants cause distinct disorders via distinct endolysosomal defects — supported [PMID 35652444; 25233840].

Refuted / excluded: - Environmental, infectious, or chromosomal causation — excluded (purely monogenic). - Hematologic involvement as part of KAREVS — excluded in reported families (distinguishes from RBSN congenital myelofibrosis). - Complete-null mechanism — refuted (null is lethal; disease requires hypomorphic alleles).

Limitations and Future Directions

• Very small n (6 patients, 2 families): frequencies, penetrance, expressivity, prognosis, and QoL are provisional. No registry, natural-history study, or trials exist.
• No omics data (transcriptomics/proteomics/metabolomics) for patient tissues.
• Phenotypic variability unexplained (candidate modifier genes and genotype–phenotype rules need larger cohorts, e.g., via GeneMatcher).
• Priorities: identify additional families; generate allele-specific mouse/iPSC-neuron/myotube models; define natural history; explore whether modulating endolysosomal maturation or the PI3P–FYVE interaction is therapeutically tractable.

Key References (PMIDs)

• 26192890 — Kariminejad et al., 2015. Original clinical delineation; 3p24.3–p25.3 mapping (human clinical).
• 35652444 — Paul et al., 2022. RBSN gene identification; FYVE variants; separation-of-function mechanism (human clinical + in vitro).
• 25233840 — Stöckler et al., 2014. Distinct RBSN/ZFYVE20 p.Gly425Arg disorder (human clinical + in vitro).
• 29784638 — Magoulas et al., 2018 (Blood). MFANDO — syndromic congenital myelofibrosis from RBSN loss-of-function p.Gly97Arg splice variant; BMT restores hematology (human clinical + in vitro).
• 11062261 — Nielsen et al., 2000. Rabenosyn-5 as Rab5 effector, FYVE/PI3K recruitment, hVPS45 complex, Vac1p homolog (in vitro).
• 18685079 — Morrison et al., 2008. Drosophila Rbsn–Vps45 endosomal-entry module; tumor suppressor (model organism).
• 17235359 — Gengyo-Ando et al., 2007. C. elegans VPS-45/RABS-5 in RAB-5-dependent endocytosis (model organism).